BR0007174A - Compound, pharmaceutical preparation and use of compounds - Google Patents

Compound, pharmaceutical preparation and use of compounds

Info

Publication number
BR0007174A
BR0007174A BR0007174-9A BR0007174A BR0007174A BR 0007174 A BR0007174 A BR 0007174A BR 0007174 A BR0007174 A BR 0007174A BR 0007174 A BR0007174 A BR 0007174A
Authority
BR
Brazil
Prior art keywords
compounds
compound
pharmaceutical preparation
preparation
prodrugs
Prior art date
Application number
BR0007174-9A
Other languages
Portuguese (pt)
Inventor
Wilfried Lubisch
Michael Kock
Thomas Hoeger
Sabine Schult
Roland Grandel
Reinhold Mueller
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946289A external-priority patent/DE19946289A1/en
Priority claimed from DE10039610A external-priority patent/DE10039610A1/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of BR0007174A publication Critical patent/BR0007174A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"COMPOSTO, PREPARAçãO FARMACêUTICA E USO DE COMPOSTOS". A invenção refere-se aos compostos de fórmula I e às suas formas tautoméricas, às suas possíveis formas diastereoméricas e enantioméricas, e às suas pró-drogas, à preparação e ao uso dos mesmos, os valores possuindo os significados indicados na descrição."COMPOUND, PHARMACEUTICAL PREPARATION AND USE OF COMPOUNDS". The invention relates to compounds of formula I and their tautomeric forms, their possible diastereomeric and enantiomeric forms, and their prodrugs, their preparation and use, the values having the meanings indicated in the description.

BR0007174-9A 1999-09-28 2000-09-15 Compound, pharmaceutical preparation and use of compounds BR0007174A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19946289A DE19946289A1 (en) 1999-09-28 1999-09-28 Benzodiazepine derivatives, their production and use
DE10039610A DE10039610A1 (en) 2000-08-09 2000-08-09 Azepinoindole derivatives are PARP inhibitors and are useful for the treatment of neurodegenerative diseases, ischemia, tumor, septic shock, inflammation, rheumatic diseases, ARDS and diabetes mellitus
PCT/EP2000/009024 WO2001023390A2 (en) 1999-09-28 2000-09-15 Azepinoindole derivatives, the production and use thereof

Publications (1)

Publication Number Publication Date
BR0007174A true BR0007174A (en) 2001-09-04

Family

ID=26006691

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0007174-9A BR0007174A (en) 1999-09-28 2000-09-15 Compound, pharmaceutical preparation and use of compounds

Country Status (17)

Country Link
EP (1) EP1183259A2 (en)
JP (1) JP2003510328A (en)
KR (1) KR20010087401A (en)
CN (1) CN1374961A (en)
AU (1) AU1271201A (en)
BG (1) BG105650A (en)
BR (1) BR0007174A (en)
CA (1) CA2352194A1 (en)
CZ (1) CZ20012373A3 (en)
HK (1) HK1048999A1 (en)
HU (1) HUP0104917A3 (en)
IL (1) IL143349A0 (en)
NO (1) NO20012567L (en)
PL (1) PL347885A1 (en)
SK (1) SK8842001A3 (en)
TR (1) TR200101499T1 (en)
WO (1) WO2001023390A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781711B2 (en) 1999-01-11 2005-06-09 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
DE60142921D1 (en) * 2000-12-01 2010-10-07 Eisai Inc AZAPHENANTHRIDONE DERIVATIVES AND THEIR USE AS PARP INHIBITORS
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
WO2003093261A1 (en) 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
ATE405658T1 (en) 2002-07-26 2008-09-15 Basf Plant Science Gmbh NEW SELECTION PROCEDURES
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
JP5545690B2 (en) 2003-12-01 2014-07-09 クドス ファーマシューティカルズ リミテッド DNA damage repair inhibitors for cancer treatment
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (en) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Thienopyridine for treating hepatitis C
ATE541043T1 (en) 2005-03-08 2012-01-15 Basf Plant Science Gmbh EXPRESSION-ENHANCED INTRON SEQUENCE
WO2006101937A1 (en) 2005-03-18 2006-09-28 Janssen Pharmaceutica N.V. Acylhydrazones as kinase modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (en) 2006-10-17 2008-05-31 Kudos Pharm Ltd SUBSTITUTED DERIVATIVES OF 2H-FTALAZIN-1-ONA, ITS CRYSTAL FORMS, PREPARATION PROCESS AND APPLICATIONS
AU2008299721A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
UY31603A1 (en) 2008-01-23 2009-08-31 DERIVATIVES OF FTALAZINONA
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
ES2598178T5 (en) 2008-10-07 2023-12-26 Kudos Pharm Ltd Pharmaceutical formulation 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
BR112012012444A2 (en) 2009-11-27 2015-09-22 Basf Plant Science Co Gmbh "chimeric endonuclease, isolated polynucleotide, expression cassette, vector, non-human organism, method for providing a chimeric endonuclease, method for homologous polynucleotide recombination, method for targeted polynucleotide mutation, and method for homologous recombination or targeted mutation"
DE112010004583T5 (en) 2009-11-27 2012-10-18 Basf Plant Science Company Gmbh Chimeric endonucleases and applications thereof
BR112012012588B1 (en) 2009-11-27 2019-03-26 Basf Plant Science Company Gmbh ENDONUCLEASE, METHOD FOR HOMOLOGICAL RECOMBINATION OF POLINUCLEOTIDES AND METHOD FOR DIRECTED POLINUCLEOTIDE MUTATION
CA2801074A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CN108138177B9 (en) 2015-07-23 2021-08-13 法国居里学院 Use of Dbait molecules in combination with PARP inhibitors for the treatment of cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
CN110997068B (en) * 2017-05-24 2022-12-06 宾夕法尼亚大学董事会 Radiolabeled fluorescent PARP inhibitors for imaging and radiotherapy
US20200407720A1 (en) 2018-03-13 2020-12-31 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020156577A1 (en) * 2019-02-02 2020-08-06 正大天晴药业集团股份有限公司 Indolo heptamyl oxime analogue as parp inhibitor
CN114072410B (en) * 2019-08-01 2023-08-01 正大天晴药业集团股份有限公司 Indolo seven-membered acyl oxime compounds as PARP inhibitors
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202214649A (en) * 2020-07-31 2022-04-16 大陸商正大天晴藥業集團股份有限公司 Indolo heptamyl oxime analog crystal as PARP inhibitor and method for preparing same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9298198A (en) * 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
AU781711B2 (en) * 1999-01-11 2005-06-09 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
ECSP003637A (en) * 1999-08-31 2002-03-25 Agouron Pharma TRICYCLE POLY INHIBITORS (ADP-RIBOSA) POLYMERASES

Also Published As

Publication number Publication date
CA2352194A1 (en) 2001-04-05
JP2003510328A (en) 2003-03-18
HUP0104917A2 (en) 2002-04-29
EP1183259A2 (en) 2002-03-06
HUP0104917A3 (en) 2002-12-28
PL347885A1 (en) 2002-04-22
NO20012567L (en) 2001-06-25
IL143349A0 (en) 2002-04-21
TR200101499T1 (en) 2002-09-23
AU1271201A (en) 2001-04-30
CZ20012373A3 (en) 2002-05-15
BG105650A (en) 2002-02-28
SK8842001A3 (en) 2002-01-07
KR20010087401A (en) 2001-09-15
NO20012567D0 (en) 2001-05-25
WO2001023390A3 (en) 2001-12-27
WO2001023390A2 (en) 2001-04-05
HK1048999A1 (en) 2003-04-25
CN1374961A (en) 2002-10-16

Similar Documents

Publication Publication Date Title
BR0007174A (en) Compound, pharmaceutical preparation and use of compounds
BR0014326A (en) Compound, medication, use of compounds, and process for preparing compounds
BR9914221B1 (en) GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
BR9911488A (en) Compound, use of it, pharmaceutical composition, and processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound
BR0115452A (en) Compounds having fungicidal activity and processes for their manufacture and use
DE60012188D1 (en) Fungicides
FI970067A0 (en) 2 - [(dihydro) pyrazolyl-3'-oxymethylene / anilides as pesticides and fungicides
BR9713363A (en) Epothilones c, d, e and f, preparation and compositions
BR9907300A (en) Substituted oxoaza-heterocyclyl factor x inhibitors
BR0208891A (en) Dihydro-benzo [b] - [1,4] diazepin-2-one derivatives as mglur2 ii antagonists
BR9100582A (en) POLYCYCLIC 3-ARILPIRROLIDIN-2,4-DIONA DERIVATIVES, PROCESS FOR ITS PREPARATION, INSECTICID COMPOSITIONS, PROCESS FOR COMBATING INSECTS, APPLICATION, PROCESS FOR THE PREPARATION OF COMPOSITIONS
BR9810991A (en) New compounds
BR0209580A (en) Cyclohexan-1 derivatives, 4 substituted diamine
BR0214142A (en) N-Adamantyl methyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation
BR0112521A (en) Indolquinazolinones
BR0011831A (en) Compounds, process for preparing them, pharmaceutical compositions, and, use of compounds
ATE253360T1 (en) ACRIDINE DERIVATIVES TO IMPROVE THE ORAL BIOAVAILABILITY OF TAXOL
BR9911978A (en) Substituted phenyluracils
SE9801494D0 (en) Novel use
DZ2937A1 (en) New compositions of insulin sensitizers.
BR9600339A (en) Compounds pharmaceutical compositions process for the preparation of a compound and use thereof
IS5951A (en) 5HT1 antidepressant for the treatment of depression
BR0114380A (en) 1-Aminobutan-3-ol-substituted derivatives
FR2818979B1 (en) PROCESS FOR THE PREPARATION OF IMIDACLOPRIDE
DK0750616T3 (en) Acid addition salts of 2,3,4,5-tetrahydro-1H-3-benzazapine compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A, 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1925 DE 27/11/2007.